Genmab — Januar 2017
-
Det er nok lige voldsomt nok.
-
ja uden tvivl at Thorleif´s artikel har noget indflydelse på dagens kursudvikling
-
Jeg tror ikke Thorleif er særligt inde i casen. Det lød mere som om det var noget han slyngede ud om biotek generelt.
-
-
Janssen er glade for samarbejdet.
-
Skotternes begrundelse: The submitting company's justification of the treatment's costs in relation to its health benefits was not sufficient and in addition the company did not present a sufficiently robust economic and clinical analysis to gain acceptance by SMC. https://www.firstwordpharma.com/node/1446085
-
Bulder...Det er ingen artikel. Det var bare en kort kommentar.
-
Forklaringen fra Skotland stemmer meget godt overens med mit gæt.
-
I en artikel i penge sektionen Børsen 16 jan http://borsen.dk/nyheder/avisen/artikel/11/160761/artikel.html
-
Skotterne vil åbenbart have en cost-
benefitanalyse med.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind